Valerian (Valeriana officinalis)
Valerian is a flowering plant whose dried root has been used for centuries as a herbal sleep aid. In the UK it is sold as an MHRA-registered Traditional Herbal Medicine (look for the THR product licence number on the pack) for "symptomatic relief of sleep disturbances" and "mild mental stress and to aid sleep" — based on traditional use, not modern efficacy trials. UK brand examples include A. Vogel Dormeasan, Schwabe Karma Mood, Boots Sleepwell, and Pukka Night Time. Camden Medicals does NOT stock a single-active valerian SKU. Two practical things to know if you're considering valerian: First, the effect builds gradually. Trial evidence (Shinjyo 2020 meta-analysis of 60 studies, n=6,894) shows modest sleep-quality improvement over 2-4 weeks of regular evening use — it is NOT a take-it-tonight-and-it-works pill. People expecting a fast hit are often disappointed; it works more like a gentle nudge over time. Second, valerian works on the same brain system that benzodiazepines (Valium, Xanax) act on, but much more gently. It is generally well-tolerated but causes next-morning drowsiness in some users — be careful with driving — and the effect adds to alcohol or other sedating medicines. Pregnancy and breastfeeding: NOT recommended.
Camden Medicals editorial · Last reviewed 6 May 2026 · Next review May 2027
- Cross-checked against
- NHS
- NICE
- BNF
- EFSA
- FSA
Camden's editorial team independently graded each health claim below on the strength of the published evidence — see the grade beside every condition.
- Class
- Botanical
- Typical daily dose
- UK THR-registered valerian preparations typically deliver 300-900 mg of standardised root extract per evening dose. Cochrane review trial materials clustered at 400-900 mg per evening. Standardisation by valerenic acid (typically 0.3-1.0%) is the relevant dose-response marker; 4:1 to 8:1 extract ratios are most common in THR products.
- Top use evidence
- Strong
On this page
What it is
Valerian is a perennial flowering plant whose dried root has been used as a herbal sleep aid for over 1,000 years across Europe. The characteristic strong, musky odour develops as the root dries and is a quality marker — fresh-smelling valerian root is poorly stored.
On a UK shelf you'll see valerian in three forms:
MHRA THR-registered medicinal preparations — capsules or tinctures at higher concentration. The THR licence number on the pack means MHRA has verified safety, quality, and traditional-use history (but NOT modern efficacy data — that's a separate, more demanding regulatory bar). Typical dose 300-900 mg of standardised extract in the evening.
Food-supplement valerian — lower concentration, no UK health claim allowed. Sometimes combined with hops, lemon balm, or chamomile in herbal sleep blends.
Tea bags — much lower concentration than capsules; pleasant evening drink rather than a medicinal-strength serving.
Brand names commonly seen in UK pharmacies and supermarkets: A. Vogel Dormeasan, Schwabe Karma Mood, Boots Sleepwell, Pukka Night Time, Lloyds Pharmacy Sleepeze valerian.
The combination with hops (Valerian + Humulus lupulus) is the most-trialled UK herbal sleep mix and the most-cited THR-registered combination — mechanism-additive on the same calming brain system.
Camden Medicals does NOT stock a single-active valerian SKU. This entry is the UK-anchored anchor for the sleep / calming botanical cluster (alongside chamomile, lemon balm, st-johns-wort).
At a glance
- Traditional herbal medicine for sleep difficulty. UK MHRA THR-registered (look for the product licence number on the pack).
- Effect builds over 2-4 weeks of regular evening use. NOT a fast-acting sleep tablet — expect gradual rather than immediate improvement.
- NOT recommended in pregnancy or breastfeeding. Safety data are insufficient. Talk to your midwife or GP.
- Next-morning drowsiness is the most common side effect. Be careful with driving. Adds to alcohol, benzodiazepines, opioids, and sedating antihistamines.
- Stop valerian ≥7 days before any planned surgery — additive effect with anaesthetic agents.
- Rare cases of liver problems have been reported (mostly with multi-herbal mixes, not pure valerian). If you have liver disease, talk to your GP first.
- NHS pathway for chronic insomnia: sleep hygiene + CBT for insomnia (CBT-I) first, then GP review for prescribed sleep medicines short-term. Valerian is a complementary option, not a substitute.
What people use it for
Adults with mild-to-moderate sleep difficulty exploring traditional herbal medicines
UK MHRA THR-registered valerian preparations may be marketed for "the symptomatic relief of sleep disturbances" — a traditional-use registration, not efficacy-evidenced. Cochrane systematic review evidence is mixed; trial protocols typically use 400-900 mg of standardised extract over 2-4 weeks before measuring sleep-quality improvement. Acute single-dose effect is small. UK NICE pathway for chronic insomnia (CKS Insomnia) is sleep-hygiene first, cognitive behavioural therapy for insomnia (CBTi) second, prescribed hypnotic medicines as a third-line short-term option — valerian is not in the NICE pathway. [2,8]
Popular, not provenMixedAdults with mild generalised anxiety symptoms exploring herbal options
UK MHRA THR-registered valerian preparations are also registered for "the symptomatic relief of mild symptoms of mental stress and to aid sleep". Cochrane review on valerian for anxiety (Miyasaka 2006) concluded the evidence base is too small to support clinical use. UK NICE pathway for generalised anxiety (CG113) is talking therapies first, antidepressant medication second; valerian is not in the pathway. [3]
Popular, not provenInsufficientAdults considering valerian to taper off a prescribed benzodiazepine or Z-drug
Talk to the prescribing GP. Self-substituting valerian for a prescribed sedative-hypnotic is not a UK-recognised pathway. Benzodiazepine and Z-drug withdrawal can produce rebound insomnia, anxiety, and (with abrupt cessation of long-term high-dose benzodiazepine) seizures. Tapering should be planned with clinical support; valerian may have a role as part of a structured non-pharmacological wind-down but not as a unilateral substitute. UK NHS pathway exists. [2]
Popular, not provenInsufficientPregnant or breastfeeding women, or women trying to conceive
Avoid valerian. Safety in pregnancy and lactation is insufficient; THR product literature lists both as contraindications. UK pregnancy sleep-difficulty pathway is sleep-hygiene measures plus midwife / GP review; talking therapies and (if indicated) prescribed hypnotic with specialist input. [9]
Some evidenceStrongAdults with planned surgery or anaesthesia in the next two weeks
Stop valerian ≥7-10 days before surgery. Additive interaction with anaesthetic GABA-A potentiators is documented; the perioperative sedation and recovery profile is altered. Disclose any valerian use (or any herbal supplement use) at the pre-anaesthetic assessment.
Some evidenceLimited
How it works
Valerian works on the same brain system that prescription anti-anxiety and sleep medicines target — the GABA system. The main active compound (valerenic acid) gently boosts the calming signal that GABA already sends naturally, in a similar general way to how benzodiazepines like diazepam (Valium) work, but at vastly weaker intensity. Think of it as a quiet whisper to the brain's "calm down" channel.
A second mechanism worth knowing about is the slow onset. Unlike benzodiazepines or Z-drugs (zolpidem, zopiclone) which start working within an hour of a single dose, valerian's effect builds gradually with regular evening use over 2-4 weeks. The Shinjyo 2020 meta-analysis of 60 studies and 6,894 subjects (the largest evidence synthesis to date) supports modest sleep-quality improvement at this pace; single-night studies often show much smaller effects, which is part of why the literature looks mixed if you don't account for the timeline.
The characteristic strong odour of valerian root comes from a different compound (isovaleric acid) and isn't directly responsible for the sleep effect — it's more of a quality-marker of properly-dried root. The "smell test" some herbalists use is real: weak-smelling valerian capsules often correspond to old or improperly-stored material with reduced potency.
The hepatotoxicity (liver-injury) signal in valerian is worth knowing about but should be kept in proportion. Case reports of liver injury linked to valerian-containing supplements exist — but most involve multi-herbal blends, and attributing the harm specifically to valerian (rather than a co-ingredient like kava, which has been banned in UK supplements since 2003) is often unclear. The MHRA continues to register single-active valerian under the THR scheme, suggesting the safety signal at pure-valerian doses is small.
Common myths
Myth""Valerian works on the first night.""
RealityTrial protocols report sleep-quality improvements emerging at 2-4 weeks of regular evening dosing — not acutely. Some users report a subjective effect on the first night, often indistinguishable from placebo response in trial settings. Marketing as a "take-tonight-fall-asleep" hypnotic is not supported by the trial protocols on which the THR registrations rest.
Myth""Valerian is a natural Valium.""
RealityThe two share GABA-A receptor as the broad target but clinical equivalence is not established. Diazepam (Valium) is a Prescription-Only Medicine with well-defined dose-response, narrow-therapeutic-index considerations, dependence liability, and prescribing rules. Valerian is a traditional-use registered herbal with modest and inconsistent trial evidence. The "natural Valium" framing is marketing language, not clinical equivalence; combining the two is also additive and is not advised without prescriber input.
Myth""Valerian has no side effects because it's natural.""
RealityNaturalness-as-safety arguments do not apply. Common side effects include next-morning drowsiness, dry mouth, GI upset, and vivid dreams. Rare hepatotoxicity case reports exist (mostly with multi-herbal combination products) and are flagged in the EMA Herbal Monograph. Drug interactions with CNS depressants and anaesthetic agents are documented. Pregnancy / breastfeeding contraindication is universal.
Myth""Higher dose valerian is more effective.""
RealityDose-response evidence is weak; trial materials cluster around 400-900 mg of standardised extract. Doses substantially above this range do not have proportionally stronger evidence and increase the next-morning-drowsiness signal. Quality of standardisation (valerenic acid % declared) matters more than absolute milligram on the label.
Myth""Valerian and CBD work the same way.""
RealityDifferent mechanisms entirely. Valerian acts on GABA-A receptors and has THR registration as a traditional herbal medicine in the UK. CBD acts on the endocannabinoid system and is regulated as a Novel Food in the UK with a public-list process; CBD products marketed for sleep cannot make UK sleep claims. The two should not be conflated.
What people say online
Valerian is a high-volume search cluster on TikTok and Reddit, typically under the framing "natural sleep aid" or "alternative to sleeping tablets". The discourse is mostly accurate on the gentle profile + slow onset, but two specific issues recur — the "use it like Ambien" expectation (which is wrong — valerian doesn't work that way) and silence on the next-morning drowsiness + driving caveat. This section surfaces the discourse without naming individuals.
Trending claims
- TikTok + Reddit (insomnia content)high visibility
Claim: Valerian is natural Ambien — take it tonight, sleep tonight
Reality check: NO. Valerian works on the same brain calming system as benzodiazepines and Z-drugs but at vastly weaker intensity, and the effect builds over 2-4 weeks of regular evening use rather than working acutely on the first night. The Shinjyo 2020 meta-analysis (PMID 33086877) supports modest sleep-quality improvement at this gradual pace. For fast-acting insomnia treatment, the UK NHS pathway is GP review — prescribed short-term hypnotics if appropriate, after sleep hygiene + CBT for insomnia. [6]
- TikTok (wellness content)high visibility
Claim: Valerian is safe to combine with everything — it's just a plant
Reality check: Valerian works on the same GABA brain system as benzodiazepines, Z-drugs, opioids, sedating antihistamines, and alcohol — the effects ADD UP. Next-morning drowsiness is the most common side effect and a real driving safety concern. If you take any prescribed sleep, anti-anxiety, or strong painkiller medicine, talk to your pharmacist or GP before adding valerian.
- Reddit (r/Supplements)medium visibility
Claim: Valerian damages your liver
Reality check: Rare case reports of liver injury linked to valerian- containing supplements exist — but most involve multi- herbal blends, and attributing the harm specifically to valerian (rather than a co-ingredient like kava, banned in UK supplements since 2003) is often unclear. Pure valerian at UK THR-registered doses appears safe at the population level; pre-existing liver disease is a precautionary contraindication. If you develop jaundice, dark urine, or abdominal pain, stop and contact your GP.
- TikTok (anti-medication content)medium visibility
Claim: Use valerian to taper off your sleeping tablets unilaterally
Reality check: DANGEROUS. Tapering off benzodiazepines and Z-drugs needs to be planned with the prescribing GP — abrupt cessation of long-term high-dose benzodiazepines can cause rebound insomnia, anxiety, and (rarely) seizures. Valerian may have a role as part of a structured non-pharmacological wind-down but NOT as a unilateral substitute. The UK NHS has an established benzodiazepine-tapering pathway.
Where the conversation lives
- TikTok hashtags: #valerian, #naturalsleep, #insomnia, #sleephacks, #eveningroutine
- Reddit subs: r/Supplements, r/sleep, r/insomnia, r/herbalism
- Forums: Examine.com (paid analysis), benzo-tapering communities
Questions people are searching
- Does valerian actually work for sleep?
- How long does valerian take to work?
- Is valerian safe to take every night?
- Valerian vs melatonin — which is better?
- Can I take valerian with my antidepressant?
Who drives the discourse: The discourse is driven by three influencer classes: wellness / herbalism creators (generally accurate but variable on the slow-onset framing); insomnia / sleep-specialist creators (most accurate on the realistic-expectation context); benzodiazepine-tapering advocacy creators (sometimes promote valerian as a substitute, which is risky without prescriber support). Verifera editorial does not name individuals.
Social-media trends change quickly. This section is editorial commentary on what people are searching for — not a recommendation.
Common online questions
Synthesised from the questions UK shoppers most often ask online about Valerian (Valeriana officinalis). Each answer is editorial and links to its evidence in the Sources list below.
How long does valerian take to work?
Trial-evidenced effect emerges over 2-4 weeks of regular evening dosing. Acute first-night effect is small in trial settings. Take it consistently every evening rather than intermittently as needed; if you don''t notice anything in the first 1-2 weeks, that is consistent with the trial evidence. If you don''t notice anything by week 4, valerian may not be the right ingredient for you. [8]
Can I take valerian and a sleeping tablet together?
Not without your prescribing GP's input. Valerian is a GABA-A modulator and so is the prescribed sleeping tablet (zopiclone, zolpidem, temazepam, nitrazepam, diazepam used as a hypnotic). Adding valerian on top doubles up on the same mechanism — additive sedation, increased fall risk, next-morning impairment. If the prescribed hypnotic is not working, the conversation is with the prescriber, not unilateral self-supplementation. [2]
Can I drive after taking valerian?
UK MHRA THR-registered valerian products carry a "may affect ability to drive or operate machinery" warning. The next-morning drowsiness signal is dose-dependent and individual. If you are taking a UK THR-registered preparation for the first time, avoid driving until you know how it affects you.
Why does valerian smell so bad?
Isovaleric acid and other volatile constituents are released as the dried root cures, producing the characteristic sweet-musky-cheese odour. The smell is normal and not a quality concern; tablets and capsules typically reduce the olfactory exposure compared to bulk root or tincture forms.
Should I stop valerian before surgery?
Yes — stop ≥7-10 days before planned surgery. Valerian potentiates GABA-A signalling and may interact with anaesthetic agents. Mention any herbal-supplement use to your anaesthetist at the pre-anaesthetic assessment.
⚖️ The official position
What may lawfully be claimed about Valerian (Valeriana officinalis) in Great Britain. This is a regulatory position, not an evidence grade.
No health claim is authorised for this use in Great Britain.
Valerian (Valeriana officinalis) has a history of traditional use. Authorised health claims require a positive EFSA scientific opinion; none has been issued for this use.
UK regulatory landscape
UK regulatory tier: Food supplement
Valerian sits across two UK regulatory tiers. Medicinal-strength preparations are registered under the MHRA Traditional Herbal Registration (THR) scheme for "symptomatic relief of sleep disturbances" and "symptomatic relief of mild symptoms of mental stress and to aid sleep" — under the mandatory "based on traditional use only" qualifier. Lower-strength tea bags and supplements are sold as food supplements under the UK Food Supplements Regulations with no UK health claim permitted. EFSA evaluations of valerian botanical claims remain on hold. Multiple UK consumer brands hold THR registrations (A. Vogel Dormeasan, Schwabe Karma Mood, Pukka Night Time, Boots Sleepwell). The European Medicines Agency Herbal Monograph (HMPC) supports the THR registration framework.
What crosses the tier
| Condition | Crosses to |
|---|---|
| Marketing as a treatment for diagnosed chronic insomnia, generalised anxiety, or panic disorder | Crosses to medicinal-product claims outside THR scope; UK NICE pathways (CKS Insomnia, CG113 anxiety) do not include valerian; ASA / CAP Code §15 enforcement. |
| Marketing as clinical equivalent to prescribed sedative-hypnotic (Z-drugs, benzodiazepines) | Outside THR scope; effect size and mechanism are not equivalent; misleading-claim enforcement risk. |
| Marketing as suitable for benzodiazepine tapering without prescriber oversight | Patient-safety risk — abrupt benzodiazepine cessation can cause rebound insomnia, anxiety, and seizures. UK NHS has an established tapering pathway. |
| Higher-strength preparation marketed without THR registration | MHRA Borderline Section may classify as unlicensed medicinal product. |
Permitted claims
THR-registered preparations: registered indication wording "based on traditional use only." Food-supplement valerian: no UK health claim permitted. Mandatory: driving / machinery warning on THR labels.
Cross-jurisdiction note
Valerian is widely available across UK and international markets at supplement and tea tier. Germany has more substantial phytotherapy practice with valerian than the UK, and several large valerian RCTs originate from German research groups. UK NICE Insomnia pathway prioritises sleep hygiene and CBT-I; valerian is not in the pathway despite Cochrane-tier evidence.
UK regulatory rules evolve. This summary is editorial — businesses should consult regulatory counsel; consumers should consult their pharmacist or GP.
🔬 Camden’s evidence review
The research Camden reviewed, graded on its strength. This is our own appraisal — it sits beneath the official guidance above, never above it.
Insomnia / sleep quality in adults
MixedEvidencemixedCochrane systematic review (Bent 2006 and subsequent updates) of valerian for insomnia pooled 16 RCTs covering ~1100 participants and reported modest and inconsistent improvements in sleep quality, with substantial heterogeneity between trials and study-quality limitations. Some trials report subjective sleep-quality improvement without polysomnography corroboration. Trial extract doses were 400-900 mg/evening of standardised aqueous or aqueous-ethanolic extract, taken over 2-4 weeks. The EMA Herbal Monograph (HMPC) supports the THR registration framework. UK NICE chronic-insomnia pathway is sleep hygiene + CBTi first; valerian is not in the pathway. [8,10,11,2]
Generalised anxiety disorder / anxiety symptoms in adults
InsufficientEvidenceinsufficientCochrane systematic review (Miyasaka 2006) on valerian for anxiety disorders concluded the evidence base was too limited to support clinical use. UK NICE CG113 (generalised anxiety) does not list valerian. THR registration permits the "mild symptoms of mental stress" wording on the basis of traditional use, not efficacy evidence. [3]
Menopausal sleep disturbance
LimitedEvidencelimitedA small number of RCTs in postmenopausal women have reported sleep-quality improvement on valerian. Trial sizes are small and effect sizes modest. UK NICE menopause pathway (NG23) is sleep hygiene + HRT consideration; valerian is not in the pathway. [12]
Restless legs syndrome (RLS)
InsufficientEvidenceinsufficientLimited trial evidence of valerian for RLS. UK NICE pathway for RLS includes ferritin / iron-status assessment and prescribed dopaminergic agents; valerian is not in the pathway. [13]
Paediatric sleep
InsufficientEvidenceinsufficientTrial evidence of valerian in children with sleep difficulty is small and inconsistent. THR registrations exclude paediatric indications. UK NICE pathway for paediatric sleep difficulty is sleep hygiene + parental support + (where indicated) specialist paediatric input. Valerian is not appropriate for self-supplementation in children.
Effect matrix — per-condition evidence
Per-outcome summary of the published trial corpus: dose ranges studied, duration, evidence grade, and direction of effect. Each row is a citable claim.
| Outcome | Population | Dose | Duration | Evidence | Direction | Sources |
|---|---|---|---|---|---|---|
| Subjective sleep quality | adults | 400–900 mg | 2–12 wk | ModerateEvidencemoderate | improvement | PMID 33086877 PMID 17145239 PMID 20347389 |
| Shinjyo 2020 meta-analysis (60 studies overall; sleep-quality sub-analysis 10 studies n=1,065). Modest but consistent improvement when extract quality is controlled. Whole-root / rhizome preparations more reliable than older valepotriate extracts. UK NHS first-line for insomnia is sleep hygiene + CBT-i; valerian sits within the THR-registered self-management space. | ||||||
| Sleep-onset latency | adults | 400–900 mg | 1–4 wk | LimitedEvidencelimited | improvement | PMID 33086877 |
| Within the Shinjyo meta-analysis sleep-quality cluster — sleep-onset latency is a sub-endpoint with weaker individual signal than overall subjective sleep quality. LIMITED grade reflects the smaller per-endpoint trial sample. | ||||||
| Anxiety symptoms (non-clinical) | adults | 400–900 mg | 2–12 wk | LimitedEvidencelimited | improvement | PMID 33086877 |
| Shinjyo 2020 anxiety sub-meta-analysis 8 studies n=535. Smaller sample than sleep endpoint; effect direction consistent but evidence base less mature. Not a substitute for clinical anxiety pathway (NICE CG113). | ||||||
| Sleep in critically ill (ICU) adults | adults | — | — | InsufficientEvidenceinsufficient | not assessed | PMID 26439374 |
| Hu 2015 Cochrane review of non-pharmacological sleep interventions in ICU — valerian-specific evidence in this setting was very limited. Listed only to acknowledge the canonical Cochrane reference; not a basis for any consumer recommendation. ICU sleep is a specialist medical context. | ||||||
Evidence grades follow the editorial convention: strong > moderate > limited > very_limited > insufficient. Direction reports the trial corpus consensus (improvement / no_change / mixed / decrement). Schema cross-emitted at MedicalSubstance.relevantClinicalCondition[].
Clinical literature review
Valerian has the largest single-active clinical evidence base of any UK calming botanical. The Shinjyo 2020 systematic review and meta-analysis (PMID 33086877) is the most-up-to- date evidence synthesis — 60 studies, 6,894 subjects across sleep and anxiety endpoints, with subjective sleep-quality meta-analysis from 10 studies (n=1,065) and anxiety meta- analysis from 8 studies (n=535). The review identifies inconsistent outcomes across trials as primarily attributable to variable herbal-extract quality (different valerenic acid content across products at the same milligram dose); when whole-root preparations of consistent quality were compared, effect sizes were more consistent. The Cochrane sleep- promotion review for ICU contexts (Hu 2015, PMID 26439374) covers valerian among other non-pharmacological sleep interventions. The earlier Bent 2006 Cochrane review on valerian for insomnia reported modest and inconsistent benefit but was published before more recent UK-pharmacopoeia standardisation work that Shinjyo 2020 incorporates.
Key trials
Shinjyo N et al. · 2020 · J Evid Based Integr Med · PMID 33086877
Finding: 60 studies of valerian for sleep problems and associated disorders. Subjective sleep-quality meta-analysis (10 studies n=1,065) and anxiety reduction meta-analysis (8 studies n=535) showed modest but consistent improvement. Inconsistency in earlier reviews was primarily due to variable herbal-extract quality; whole-root / rhizome preparations of consistent quality showed more reliable effects. No severe adverse events at ages 7-80.
Relevance: The most comprehensive evidence synthesis on valerian to date. Identifies extract-quality variability as the key confounder in older trial heterogeneity — important for UK consumers choosing between products.
Hu RF et al. · 2015 · Cochrane Database Syst Rev · PMID 26439374
Finding: Reviews non-pharmacological sleep interventions for critically ill adults including valerian acupressure (among earplugs, eye masks, music, relaxation, foot baths, massage). Earplugs and eye masks showed lower delirium incidence and better total sleep time. Valerian-specific evidence in the ICU setting was limited.
Relevance: Cochrane-tier evidence on sleep-promotion interventions generally; specific valerian role in ICU context limited. Cited here as the canonical Cochrane reference within the sleep-promotion non-pharmacological literature.
Systematic reviews
- pmid:33086877
Shinjyo 2020 meta-analysis 60 studies n=6,894 — modest but consistent sleep-quality + anxiety improvement when herbal-extract quality is controlled. Identifies whole- root / rhizome preparations as the most-reliable form.
Evidence quality summary
Subjective sleep quality — MODERATE certainty (Shinjyo 2020 n=6,894 meta-analysis; variable extract quality is the main source of trial heterogeneity). Anxiety reduction — LIMITED- MODERATE certainty (smaller meta-analysis sample, less robust than for sleep). Combination with hops / lemon balm — MODERATE certainty for THR-registered combinations. Pregnancy / lactation — INSUFFICIENT data; precautionary universal avoidance under UK MHRA THR product literature. Hepatotoxicity — small case-report signal mostly with multi-herbal blends; pure-valerian risk is small but warrants disclosure if pre-existing liver disease.
Known gaps
- Head-to-head trials of valerian vs prescription hypnotics (Z-drugs, benzodiazepines) are limited.
- Long-term safety data (>12 months) is sparse.
- Older trials are dominated by valepotriate-containing extracts; modern UK trial materials are valerenic-acid-standardised — direct cross-trial comparison is limited.
- Paediatric efficacy + safety data are absent (THR registrations exclude paediatric use).
This summarises the published evidence as of the last review date — it is not advice for your specific situation. Talk to your pharmacist or GP.
Safety
Valerian is one of the better-tolerated UK herbal sleep ingredients. The realistic concerns are next-morning drowsiness (additive with alcohol and CNS depressants), pregnancy / breastfeeding avoidance, and pre-surgery stop-7-10-days-before. Hepatotoxicity is rare and mostly associated with multi-herbal combination products.
Talk to your pharmacist or GP first if you:
- You take a prescribed sedative-hypnotic (zopiclone, zolpidem, temazepam, nitrazepam, lorazepam, diazepam, melatonin) — additive sedation, increased fall risk.
- You take a sedating antidepressant (mirtazapine, trazodone, amitriptyline) — additive sedation.
- You take an opioid analgesic — additive sedation, increased respiratory-depression risk at high opioid doses.
- You take sedating antihistamines (chlorphenamine, promethazine, hydroxyzine) — additive sedation.
- You drink alcohol regularly or are using valerian for alcohol-related sleep disturbance — additive sedation; alcohol itself disrupts sleep architecture.
- You have planned surgery or anaesthesia in the next two weeks — stop ≥7-10 days before.
- You have a history of liver disease or are on hepatotoxic medication — pre-existing liver concern is a relative contraindication.
- You are pregnant, breastfeeding, or trying to conceive — avoid.
- You are giving any supplement to a child for sleep — talk to a paediatrician; valerian is not registered for paediatric use.
Common side effects: Next-morning drowsiness, dry mouth, mild GI upset, vivid dreams. Rare: paradoxical agitation, headache, mild liver-enzyme elevation.
Pregnancy and breastfeeding
NOT recommended in pregnancy. Safety data are insufficient and UK MHRA Traditional Herbal Registration product literature lists pregnancy as a contraindication for medicinal-strength preparations. Talk to your midwife or GP about pregnancy- compatible sleep approaches (sleep-hygiene measures + GP / midwife review if needed).
Same precautionary position as pregnancy. Safety data are insufficient. Talk to your midwife or health visitor.
Talk to your GP, midwife, or pharmacist before starting any supplement during pregnancy or breastfeeding.
More clinical detail (for clinicians and informed readers)
Contraindications
- Children under 12 (THR registrations exclude this age group).
- Pregnancy and breastfeeding.
- Pre-existing liver disease (relative contraindication).
- Concurrent use of multiple CNS depressants without prescriber oversight.
- Hypersensitivity to valerian or any product constituent.
Drug interactions
Benzodiazepines (diazepam, lorazepam, clonazepam, temazepam, nitrazepam) and Z-drugs (zolpidem, zopiclone) · high
Effect: Additive sedation, increased next-day impairment, increased fall risk. At high doses, raised respiratory-depression risk. Combining concentrated valerian extract with prescribed sleep / anti-anxiety medicines is generally not recommended without prescriber oversight.
Mechanism: Both act on the GABA-A receptor system, though valerenic acid binds at a different site from benzodiazepines / Z-drugs. The sedative effects ADD UP.
Action: Talk to your prescribing GP or pharmacist BEFORE adding valerian if you take any prescribed sleep / anti-anxiety medicine. Do NOT use valerian to taper off prescribed sleeping tablets unilaterally — the UK NHS has an established tapering pathway.
Source: BNF benzodiazepines + Z-drugs + UK NHS benzodiazepine-tapering guidance
Opioid analgesics (codeine, tramadol, morphine, oxycodone, fentanyl) · high
Effect: Additive sedation. At higher opioid doses or in older adults, increased respiratory-depression risk.
Mechanism: Both contribute to CNS depression via different pathways (opioids via μ-receptor; valerian via GABA-A). Combined effect can be substantially greater than expected.
Action: Tell your prescribing GP or pharmacist about valerian use if you take prescribed opioid pain medication.
Source: BNF opioid analgesics + MHRA opioid prescribing guidance
Anaesthetic agents (propofol, midazolam, volatile anaesthetics) · high
Effect: Additive GABAergic effect during induction of anaesthesia. Documented in anaesthetic literature; stop ≥7-10 days before any planned surgery.
Mechanism: Anaesthetic agents work largely through the GABA system; valerian potentiates the same system.
Action: Tell your anaesthetist and surgical team about valerian use at the pre-operative assessment. Stop ≥7-10 days before planned surgery.
Source: BNF anaesthetic agents + Royal College of Anaesthetists pre-op guidance
Sedating antidepressants (mirtazapine, trazodone, amitriptyline, doxepin) — additive sedation; tell your prescriber.
Sedating antihistamines (chlorphenamine, promethazine, hydroxyzine, diphenhydramine) — additive sedation; tell your pharmacist.
Alcohol — additive sedation and CNS depression. Avoid combination.
Other herbal sedatives (chamomile, lemon balm, hops, passionflower, melatonin) — additive sedation. THR co-formulations are designed for this; stack with awareness.
CYP3A4-metabolised medications — modest in vitro CYP3A4 inhibition or induction signals reported; clinical relevance debated. Disclose use to prescriber.
P-glycoprotein substrates — modest in vitro signals; clinical relevance debated.
Tell your prescriber if you take any of these combinations. This is not personalised advice.
This is not an exhaustive list. Always tell your prescriber and pharmacist about every supplement you take.
Common side effects
- Next-morning drowsiness, particularly with higher doses or combined with CNS depressants.
- Dry mouth.
- Mild GI upset (nausea, abdominal cramping).
- Vivid or unusual dreams.
- Headache (usually mild).
Rare side effects
- Paradoxical agitation or insomnia (mostly reported in older adults).
- Hepatotoxicity — rare case reports, mostly with multi-herbal combination products. Discontinue and seek medical input if jaundice, dark urine, or abdominal pain develop.
- Withdrawal-like symptoms (rebound insomnia, anxiety) on abrupt discontinuation after prolonged use — taper rather than stop suddenly.
- Allergic reactions (rare).
How to take it
- Typical supplemental range
- UK THR-registered valerian preparations typically deliver 300-900 mg of standardised root extract per evening dose. Cochrane review trial materials clustered at 400-900 mg per evening. Standardisation by valerenic acid (typically 0.3-1.0%) is the relevant dose-response marker; 4:1 to 8:1 extract ratios are most common in THR products.
- Timing
- Taken in the evening, 30-60 minutes before bed for sleep indications. Effects emerge over 2-4 weeks of regular use; acute first-night effect is small. Avoid driving after taking; do not combine with alcohol or other CNS depressants.
How to spot quality
Look for
- MHRA THR licence number on the pack ("THR XXXXX/XXXX") for traditional-use registered products. THR registration permits the sleep-disturbance / mild-stress wording.
- Standardisation declared: valerenic acid percentage (typical 0.3-1.0%) — the relevant marker for trial-matched material.
- Plant species declared as Valeriana officinalis specifically (other Valeriana species — V. edulis, V. wallichii, V. jatamansi — have different chemotypes; trial evidence is concentrated on V. officinalis).
- Extract ratio declared (4:1 to 8:1 typical) and extract type (aqueous, aqueous-ethanolic).
- Driving / machinery warning visible on the pack (THR labelling requirement).
- GMP-certified manufacture.
Red flags
- No MHRA THR licence number — the product cannot legally make sleep-disturbance or mental-stress claims in the UK if it is not a THR-registered preparation. Lower-strength food-supplement valerian is sold but cannot make UK health claims.
- No valerenic acid percentage declared.
- Generic "Valerian root powder" at the same milligram as standardised extract — unstandardised material.
- Marketing as "natural Valium" / clinical-equivalence to prescribed sedative-hypnotic.
- "Take tonight, sleep tonight" / acute hypnotic framing.
- Combination products with kava (banned in UK as a food supplement since 2003 because of hepatotoxicity), or with herbs not listed individually on the spec sheet.
- Marketing for paediatric use (THR registrations exclude children).
Commonly combined with
Other ingredients that share a biological pathway, cofactor relationship, or evidence-backed protocol with this one. Mechanisms below cite primary physiology — not folk pairing. Doses are literature ranges, not recommendations. Talk to your pharmacist or GP before changing your stack, especially if you take prescription medication.
Hops (Humulus lupulus)
Moderate evidenceThe most-trialled UK herbal sleep combination — valerian-hops fixed-combination THR-registered preparations have been the principal trial format for herbal sleep evidence.
Both valerian and hops modulate GABA-A receptor signalling — the same broad target as benzodiazepines and Z-drugs — but at different binding sites. Valerenic acid binds the GABA-A β-subunit at a site distinct from the benzodiazepine site. Hops contains 8-prenylnaringenin (8-PN), the most potent phytoestrogen identified in nature, plus humulone and lupulone bitter acids; the sedative effect of hops appears to be mediated through GABAergic and adenosine-A1 mechanisms rather than the phytoestrogen content.
The Schwabe Pharma fixed-combination preparation Ze 91019 (valerian root extract + hops cone extract) is the most-trialled herbal sleep product. Trial materials show modest improvements in sleep-onset latency and sleep-quality measures over 2-4 weeks of evening dosing — broadly comparable to valerian alone in pooled analyses. The combination rationale is mechanism-additive (two GABA-A modulators at different binding sites + adenosine modulation from hops) and is the basis for the THR registration of multiple UK herbal sleep brands.
8-prenylnaringenin's phytoestrogen activity adds a separate consideration for hops use in oestrogen-sensitive contexts (breast cancer history, oestrogen-receptor-positive disease) — see Camden's hops for detail. Valerian alone does not have this consideration.
Evidence: Schwabe Pharma Ze 91019 valerian-hops trial set is the largest herbal-sleep combination trial body. EMA Herbal Monographs for both valerian and hops support the THR co-registration framework. [8]
Doses studied: Valerian root extract 250-500 mg + hops cone extract 60-200 mg per evening dose, in standardised THR-registered preparations. Effects emerge over 2-4 weeks.
Lemon Balm (Melissa officinalis)
Limited evidenceCalm-cluster THR co-formulation — valerian + lemon balm + chamomile is the classic UK herbal sleep / mild-stress mix.
Lemon balm (Melissa officinalis) shares the THR registered indications "relief of mild symptoms of mental stress and to aid sleep" with valerian and is frequently co-formulated in UK herbal calm products. Mechanism overlaps with valerian on the GABA-A axis (rosmarinic acid and other lemon-balm constituents inhibit GABA transaminase, increasing local GABA availability) but adds cholinergic-receptor binding and modest 5-HT modulation.
The combination is mechanism-additive but trial evidence specific to the combination is limited; most trial protocols test either valerian alone, lemon balm alone, or three-herb combinations including chamomile or passionflower. Camden's lemon-balm carries the lemon-balm-specific safety considerations including the mild thyroid-binding signal in vitro.
Evidence: Mechanism overlap (GABA-A) plus cholinergic complement is mechanistically coherent. THR co-registrations exist. Direct combination trials on hard sleep endpoints are limited.
Doses studied: Valerian root extract 200-500 mg + lemon balm leaf extract 80-300 mg, evening dose, in standardised THR preparations.
L-Theanine
Limited evidenceCalm-cluster non-herbal partner — l-theanine adds glutamatergic / alpha-wave-EEG modulation alongside valerian's GABA-A axis.
L-theanine is an amino acid found in tea (Camellia sinensis) leaves with a distinctive pharmacological profile — it crosses the blood-brain barrier, modulates glutamate signalling (NMDA antagonism), and produces an alpha-wave EEG pattern in healthy adults. The mechanism is distinct from valerian's GABA-A modulation, making the combination mechanism-complementary rather than mechanism-additive.
L-theanine is not THR-registered (it is a food supplement, not a traditional herbal medicine) and EFSA's Article 13 evaluation of l-theanine claims is on hold. The combination appears in modern sleep / calm formulations marketed as non-sedating evening adjuncts. Trial evidence on the combination specifically is small; each component has its own modest trial body.
Evidence: Mechanism complementary (GABA-A modulator plus glutamate modulator). Direct combination trial evidence is small.
Doses studied: Valerian root extract 200-500 mg + l-theanine 100-400 mg, evening dose. l-theanine is not sedating and may also be used during the day for calm framing without the sleep-onset framing.
Magnesium
Limited evidenceSleep-cluster mineral partner — magnesium modulates GABAergic and NMDA signalling alongside valerian's GABA-A axis.
Magnesium is a cofactor for over 300 enzymatic reactions and a physiological NMDA-receptor antagonist (the magnesium block of the NMDA channel pore is voltage-dependent and tonically active at resting membrane potential). Magnesium also modulates GABA-A receptor function through positive allosteric effects in cell-biology models. Magnesium deficiency in animal models produces sleep-onset latency increases, REM disruption, and anxiety-like behaviour.
In human trials, magnesium glycinate or magnesium bisglycinate at 200-400 mg/evening has been studied for sleep quality with modest effect sizes — broadly comparable to or smaller than valerian. The combination is mechanism-additive (different facets of GABAergic and glutamatergic signalling). Magnesium also delivers a separate UK Article 13.1 authorised claim ("Magnesium contributes to normal psychological function") that valerian does not.
Evidence: Magnesium-NMDA-GABA mechanism well-established. Trial evidence for magnesium alone on sleep is modest; combination with valerian not directly trialled. UK Article 13.1 magnesium psychological- function claim authorised. [5]
Doses studied: Valerian 300-600 mg + magnesium glycinate or bisglycinate 200-400 mg (40-80 mg elemental magnesium), evening dose.
Found in Camden: Aurifera™ Magnesium Complex 120 Capsules
Tart Cherry (Montmorency)
Limited evidenceSleep-cluster pairing — different mechanisms (GABA-A modulation vs melatonin / anti-inflammatory).
Valerian valerenic acid GABA-A modulation; tart-cherry anthocyanins + melatonin / tryptophan. Mechanism complementary.
Evidence: Camden valerian covers cluster.
Doses studied: 1500 mg tart-cherry + 300-500 mg valerian root extract evening.
Verifera™ editorial perspective
Why it matters. Valerian is the most-trialled herbal sleep aid in the UK and the anchor of the calming-herbal cluster on UK shelves. The editorial position is that this entry should set expectations honestly — valerian is a slow, gentle, modest sleep aid that works over weeks, NOT a fast hit equivalent to a prescription hypnotic — and surface the next-morning drowsiness + driving caveat that catches first-time users by surprise.
Where Camden lands. Camden Medicals does NOT stock a single-active valerian SKU. Camden retails oral food supplements + topical cosmetic ingredients; medicinal-strength herbal preparations are registered separately under the MHRA THR scheme. This entry exists as the UK-anchored anchor for the sleep / calming botanical cluster.
If you want to explore further. For occasional sleep difficulty: a 2-4 week trial of a UK MHRA-registered THR valerian product at the label-recommended dose, taken consistently each evening 30-60 minutes before bed. Don't expect first-night dramatic effect. For chronic insomnia (sleep problems persisting >3 months that affect daytime function), the UK NHS pathway is sleep hygiene + CBT for insomnia (CBT-I) via GP referral — both are evidence-based and NHS-accessible. For anxiety symptoms: UK NICE CG113 (talking therapies + prescribed antidepressants if needed).
How this entry was researched
Authoritative sources consulted:
- NHS sleep + insomnia + benzodiazepine-tapering pages
- NICE CKS Insomnia + CG113 (Generalised anxiety) + benzodiazepine-tapering guidance
- BNF benzodiazepines + Z-drugs
- UK MHRA Traditional Herbal Registration (THR) scheme — herbal medicines register
- GB Nutrition and Health Claims (NHC) Register — no authorised claim
- European Medicines Agency HMPC Valerian Monograph
- PubMed (via E-utilities MCP)
PubMed search terms:
valerian root insomnia systematic review randomizedValeriana officinalis sleep meta-analysis
Literature search date: 2026-05-12
Sources listed are those consulted by the Verifera™ editorial team. Readers should verify against current authoritative sources.